Adjuvant tyrosine kinase inhibitors plus anti-PD-1 therapy reduce recurrence in high-risk hepatocellular carcinoma after resection

Background/aimsNo standardized adjuvant treatment has been established for patients with hepatocellular carcinoma (HCC) following curative resection. This study aimed to evaluate the efficacy and safety of adjuvant tyrosine kinase inhibitors (TKIs) in combination with anti-programmed death-1 (PD-1)...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Jiaxin Li, Yukun Sun, Ziniu Liu, Jianwen Huang, Jian Wu, Yun Huang, Yali Gao, Baomin Chen, Qiang He
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Frontiers Media S.A. 2025-11-01
Reeks:	Frontiers in Oncology
Onderwerpen:	hepatocellular carcinoma high risk of recurrence tyrosine kinase inhibitors (TKIs) anti-PD-1 antibodies postoperative adjuvant therapy
Online toegang:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1710602/full
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!